-- Agenus Webcast and Conference Call Scheduled for Today at 8:30a.m.ET -- FOSTER CITY, Calif. and LEXINGTON, Mass., Dec. 20, 2018 / PRNewswire / -- Gilead Sciences, Inc. (NASDAQ: GILD) and Agenus Inc. (NASDAQ: AGEN) announced today the companies have entered into an immuno-oncology (I-O)

LEXINGTON, Mass., Nov. 13, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, and adoptive cell therapies 1 , today announced the election of Dr. Allison Jeynes-Ellis to Agenus' Board of Directors and the

LEXINGTON, Mass., Nov. 13, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , announced today that Dr. Jennifer Buell, Chief External Affairs Officer at Agenus, will make a

- AutoSynVax™ (ASV™), AGEN2003 clinical trials data - Novel targets in colorectal carcinoma (CRC) for off-the-shelf vaccine with pan indication development potential - AGEN2373, a novel, potential best-in-class anti-CD137 antibody for the treatment of human malignancies, is well-tolerated in

- 130 patients treated with Agenus' PD-1 & CTLA-4; clinical benefit >63% treated - Recent FDA meeting confirms path to BLA filing; targeted for 2020 - Next-Gen CTLA-4 IND filed; four INDs filed year to date - Two INDs for First-In-Class bispecifics on track for year end - Partnership discussions

LEXINGTON, Mass., Oct. 31, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , will release its third quarter 2018 financial results before the market opens on Tuesday,

- Patients treated with Agenus' PD-1 & CTLA-4 antibodies show durable clinical benefit 1  in early analyses LEXINGTON, Mass., Oct. 20 ,  2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell

- AGEN PD-1 antibody (AGEN2034) shows early signs of clinical activity in patients with cervical cancer - AGEN PD-1 & CTLA-4 (AGEN1884) is the most advanced combination in 2L cervical cancer LEXINGTON, Mass., Oct. 9, 2018 / PRNewswire / -- Agenus Inc.

LEXINGTON, Mass., Sept. 28, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , announced today that Dr. Jennifer Buell, Chief External Affairs Officer at Agenus, will make a

LEXINGTON, Mass., Sept. 21, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , today announced the closing of its non-dilutive royalty transaction with XOMA Corporation

- Payment of $5M received for initiation of Phase 1 trial of LAG-3 antibody - Eligible for up to an additional $505 million for milestones plus royalties on sales LEXINGTON, Mass., Sept. 17, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of

LEXINGTON, Mass., Sept. 5 ,  2018 / PRNewswire / -- AgenTus Therapeutics, a subsidiary of Agenus Inc. (NASDAQ: AGEN), dedicated to advancing breakthrough "living drugs" for potentially curative treatments for patients with cancer, announced today that Dr. Cherylene Plewa, Senior Director, Molecular

LEXINGTON, Mass., Sept. 4, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , announced today that Jennifer Buell, Ph.D., Chief Communications and External Affairs

- Payment of $4M received for initiation of phase 1 trial - Up to additional $95 million for milestones plus royalties on sales LEXINGTON, Mass., Aug. 15, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer

- Cash milestones earned from Merck & Incyte - Three INDs filed and 3 more to be filed during 2018 - CTLA-4 & PD-1 trials treated more than 115 patients; clinical benefit confirmed LEXINGTON, Mass. , Aug. 9, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN ), an immuno-oncology (I-O) company with a

LEXINGTON, Mass., Aug. 2, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , will release its second quarter 2018 financial results before the market opens on Thursday,

-- Sunil Gupta, MD, named Vice President Regulatory & Pharmacovigilance -- Anna Wijatyk, MD, named Vice President Clinical Development LEXINGTON, Mass., July 16, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with clinical stage checkpoint antibodies, a pipeline of

LEXINGTON, Mass., June 20, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1  invites investors and the general public to attend its Annual Meeting of Stockholders to begin

-- Novel discovery improves the immunological activity of certain cancer fighting antibodies -- Agenus' next generation anti-CTLA-4 antibody (AGEN1181) developed using this technology is slated for IND in 2018 LEXINGTON, Mass., June 12, 2018 / PRNewswire / -- A study published in Cancer Cell

LEXINGTON, Mass., June 6 ,  2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , announced today that Jennifer Buell, Ph.D., Chief Communications and External Affairs Officer

- AGEN1884 and AGEN2034 produce clinical benefit 2  in 31% and 42% of patients respectively - Combination trial of AGEN1884 plus AGEN2034 in 2L cervical cancer ongoing to support BLA LEXINGTON, Mass., June 4 ,  2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a

- AGEN1884 (CTLA-4) and AGEN2034 (PD-1) show objective clinical responses - More than 100 patients treated with AGEN1884 and AGEN2034 - Combination trial has commenced in cervical cancer LEXINGTON, Mass., May 17 ,  2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a

Agenus to host conference call and webcast today at 11am ET LEXINGTON, Mass. , May 7, 2018 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN ), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies 1 , provided a corporate update and

LEXINGTON, Mass., May 7 ,  2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , announced today that Garo Armen, Ph.D., Chairman & CEO, and Jennifer Buell, Ph.D., Chief

LEXINGTON, Mass., May 3, 2018 / PRNewswire / -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies, cancer vaccines, and adoptive cell therapies 1 , will release its first quarter 2018 financial results before the market opens on Monday, May 07,